These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 37080262)

  • 21. Aiming for cure in HBV and HDV infection.
    Petersen J; Thompson AJ; Levrero M
    J Hepatol; 2016 Oct; 65(4):835-848. PubMed ID: 27270043
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Review article: hepatitis B-current and emerging therapies.
    Yardeni D; Ghany MG
    Aliment Pharmacol Ther; 2022 Apr; 55(7):805-819. PubMed ID: 35224760
    [TBL] [Abstract][Full Text] [Related]  

  • 23. End-of-treatment HBcrAg and HBsAb levels identify durable functional cure after Peg-IFN-based therapy in patients with CHB.
    Huang D; Wu D; Wang P; Wang Y; Yuan W; Hu D; Hu J; Wang Y; Tao R; Xiao F; Zhang X; Wang X; Han M; Luo X; Yan W; Ning Q
    J Hepatol; 2022 Jul; 77(1):42-54. PubMed ID: 35149125
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A multicenter randomized-controlled trial of nucleos(t)ide analogue cessation in HBeAg-negative chronic hepatitis B.
    van Bömmel F; Stein K; Heyne R; Petersen J; Buggisch P; Berg C; Zeuzem S; Stallmach A; Sprinzl M; Schott E; Pathil-Warth A; von Arnim U; Keitel V; Lohmeyer J; Simon KG; Trautwein C; Trein A; Hüppe D; Cornberg M; Lammert F; Ingiliz P; Zachoval R; Hinrichsen H; Zipprich A; Klinker H; Schulze Zur Wiesch J; Schmiedeknecht A; Brosteanu O; Berg T
    J Hepatol; 2023 May; 78(5):926-936. PubMed ID: 37062574
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Deep sequencing shows that HBV basal core promoter and precore variants reduce the likelihood of HBsAg loss following tenofovir disoproxil fumarate therapy in HBeAg-positive chronic hepatitis B.
    Bayliss J; Yuen L; Rosenberg G; Wong D; Littlejohn M; Jackson K; Gaggar A; Kitrinos KM; Subramanian GM; Marcellin P; Buti M; Janssen HLA; Gane E; Sozzi V; Colledge D; Hammond R; Edwards R; Locarnini S; Thompson A; Revill PA
    Gut; 2017 Nov; 66(11):2013-2023. PubMed ID: 27534671
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Predicting HBsAg clearance in genotype A chronic hepatitis B using HBsAg epitope profiling: A biomarker for functional cure.
    Walsh R; Hammond R; Yuen L; Deerain J; O'Donnell T; Leary T; Cloherty G; Gaggar A; Kitrinos K; Subramanian M; Wong D; Locarnini S
    Liver Int; 2019 Nov; 39(11):2066-2076. PubMed ID: 31379058
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial.
    Bourlière M; Rabiega P; Ganne-Carrie N; Serfaty L; Marcellin P; Barthe Y; Thabut D; Guyader D; Hezode C; Picon M; Causse X; Leroy V; Bronowicki JP; Carrieri P; Riachi G; Rosa I; Attali P; Molina JM; Bacq Y; Tran A; Grangé JD; Zoulim F; Fontaine H; Alric L; Bertucci I; Bouvier-Alias M; Carrat F;
    Lancet Gastroenterol Hepatol; 2017 Mar; 2(3):177-188. PubMed ID: 28404133
    [TBL] [Abstract][Full Text] [Related]  

  • 28. APASL guidance on stopping nucleos(t)ide analogues in chronic hepatitis B patients.
    Kao JH; Jeng WJ; Ning Q; Su TH; Tseng TC; Ueno Y; Yuen MF
    Hepatol Int; 2021 Aug; 15(4):833-851. PubMed ID: 34297329
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New antiviral targets for innovative treatment concepts for hepatitis B virus and hepatitis delta virus.
    Durantel D; Zoulim F
    J Hepatol; 2016 Apr; 64(1 Suppl):S117-S131. PubMed ID: 27084032
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New strategies for the treatment of chronic hepatitis B.
    Mak LY; Cheung KS; Fung J; Seto WK; Yuen MF
    Trends Mol Med; 2022 Sep; 28(9):742-757. PubMed ID: 35780008
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Overview of New Targets for Hepatitis B Virus: Immune Modulators, Interferons, Bifunctional Peptides, Therapeutic Vaccines and Beyond.
    Lok J; Guerra Veloz MF; Agarwal K
    Clin Liver Dis; 2023 Nov; 27(4):857-876. PubMed ID: 37778774
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Advances in determining new treatments for hepatitis B infection by utilizing existing and novel biomarkers.
    Mak LY; Hui RW; Cheung KS; Fung J; Seto WK; Yuen MF
    Expert Opin Drug Discov; 2023 Apr; 18(4):401-416. PubMed ID: 36943183
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Advances in new antivirals for chronic hepatitis B.
    Tang Y; Liang H; Zeng G; Shen S; Sun J
    Chin Med J (Engl); 2022 Feb; 135(5):571-583. PubMed ID: 35120358
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chronic hepatitis B: what should be the goal for new therapies?
    Block TM; Gish R; Guo H; Mehta A; Cuconati A; Thomas London W; Guo JT
    Antiviral Res; 2013 Apr; 98(1):27-34. PubMed ID: 23391846
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [A short half-life of cccDNA offer or ignite hope for hepatitis B cure under nucleos(t)ide analogues treatment].
    Gao L; Mao TH; Peng SW; Wang J; Chen XM; Lu FM
    Zhonghua Gan Zang Bing Za Zhi; 2022 Jan; 30(1):99-102. PubMed ID: 35152678
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Direct-acting antivirals and viral RNA targeting for hepatitis B cure.
    French J; Locarnini S; Zoulim F
    Curr Opin HIV AIDS; 2020 May; 15(3):165-172. PubMed ID: 32209814
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Perspectives on stopping nucleos(t)ide analogues therapy in patients with chronic hepatitis B.
    Tout I; Lampertico P; Berg T; Asselah T
    Antiviral Res; 2021 Jan; 185():104992. PubMed ID: 33279523
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hepatitis B cure: From discovery to regulatory approval.
    Lok AS; Zoulim F; Dusheiko G; Ghany MG
    Hepatology; 2017 Oct; 66(4):1296-1313. PubMed ID: 28762522
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Seroreversion and Acute Decompensation in Chronic Hepatitis B after Discontinuation of Oral Nucleotide Analog in the Patients Achieving HBsAg Loss].
    Cho HJ; Shin SK; Kwon OS; Kim JH; Kim YS
    Korean J Gastroenterol; 2020 Nov; 76(5):256-260. PubMed ID: 33234774
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chronic Hepatitis B Infection: Current and Emerging Therapeutic Strategies.
    Singh A; Kumar J; Kumar V
    Curr Top Med Chem; 2023; 23(18):1727-1752. PubMed ID: 37069708
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.